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Abstract
Background: K-RAS mutation poses a particularly difficult problem for cancer therapy. Activating mutations in K-RAS are
common in cancers of the lung, pancreas, and colon and are associated with poor response to therapy. As such, targeted
therapies that abrogate K-RAS-induced oncogenicity would be of tremendous value.
Methods: We searched for small molecule kinase inhibitors that preferentially affect the growth of colorectal cancer cells
expressing mutant K-RAS. The mechanism of action of one inhibitor was explored using chemical and genetic approaches.
Results: We identified BAY61-3606 as an inhibitor of proliferation in colorectal cancer cells expressing mutant forms of K-
RAS, but not in isogenic cells expressing wild-type K-RAS. In addition to its anti-proliferative effects in mutant cells, BAY61-
3606 exhibited a distinct biological property in wild-type cells in that it conferred sensitivity to inhibition of RAF. In this
context, BAY61-3606 acted by inhibiting MAP4K2 (GCK), which normally activates NFkb signaling in wild-type cells in
response to inhibition of RAF. As a result of MAP4K2 inhibition, wild-type cells became sensitive to AZ-628, a RAF inhibitor,
when also treated with BAY61-3606.
Conclusions: These studies indicate that BAY61-3606 exerts distinct biological activities in different genetic contexts.
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Introduction
RAS family GTPases act as binary switches that undergo
a conformational change upon binding to GTP, allowing them to
engage a host of downstream signaling effectors including RAF,
PI3K, and RALGDS [1]. The intrinsic GTPase activity of RAS
hydrolyzes GTP to GDP, with the help of GTPase activating
protein (GAP) cofactors, to inactivate its signaling capability.
Missense mutations in codons 12, 13, 61, or 146 are common in
cancer and are associated with resistance to GAP activity, allowing
RAS to persist in the activated, GTP-bound state. Activating K-
RAS mutations occur in approximately 15% of all cancers (making
it one of the most commonly mutated oncogenes), but are
particularly common in the most lethal forms of cancer, such as
those arising in the biliary tract, colon, lung, and pancreas [2]. In
colorectal cancer, for example, K-RAS is mutated in nearly 40%
of cases [2]. Importantly, tumors with K-RAS mutations are
especially refractory to conventional and targeted therapies and
are usually associated with poor prognosis [3–5].
The main challenge of counteracting the oncogenic effects of
activated K-RAS is the inability to directly inhibit the mutant
protein. Because the signaling properties of K-RAS are enhanced
via inactivation of its GTPase activity, direct pharmacologic
inhibition of RAS is not a viable therapeutic strategy. An alternate
strategy to counteract mutant K-RAS is to inhibit its downstream
effectors, for example, the RAF-MEK-ERK (MAPK) pathway.
MEK inhibitors have received attention due their allosteric
mechanism of action, which confers extreme specificity, and their
demonstrated efficacy in melanomas and colon cancers expressing
activated B-RAF [6,7]. MEK inhibitors perform poorly in cancers
expressing mutant K-RAS, however, perhaps due to secondary
mutations that affect response or the existence of MEK-
independent signaling downstream of RAF [8,9]. Given the
presumptiveness of these scenarios, it is clear that a better
understanding of how the K-RAS signaling network operates in
cancer is needed to develop novel therapies.
In recent years, large-scale functional genomic approaches have
been employed to discover kinase targets that when knocked down
are ‘‘synthetic lethal’’ with mutant RAS. Potential therapeutic
targets that have been identified include TBK1 [10], STK33 [11],
CDK4 [12], and PLK1 [13], although it remains to be seen
whether any of these represent bona fide therapeutic targets for K-
RAS mutant cancers. Whereas understanding the mechanisms by
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which K-RAS signals through these targets is central to the design
of effective drugs, a less studied, and often overlooked, question is
why wild-type cells, which also express these targets, tolerate loss of
function of these enzymes. This issue is equally important for drug
design because the advantage of targeted therapies (over
conventional chemotherapies) is their potential selectivity for
malignant cells.
In this study, we have characterized the activity of BAY61-3606
in the context of colorectal cancer, providing insight into (1)
potential therapeutic targets for cancers expressing mutant K-RAS
and (2) pathways that regulate the response of non-mutant cells to
targeted inhibitors. BAY61-3606 was originally identified as an
orally available, ATP-competitive inhibitor of Spleen Tyrosine
Kinase (SYK) [14]. Since SYK plays an active role in in-
flammatory response, BAY61-3606 has mainly been used for
studying immune cell function. For example, BAY61-3606
suppresses antigen-induced airway inflammation in rats and B
cell migration in mice [14,15]. While all of the effects of BAY61-
3606 in immune cells are linked to its ability to inhibit SYK, it is
unknown whether BAY61-3606 has alternate targets of biological
relevance in other cellular contexts. In this study, we have
characterized two SYK-independent activities associated with
BAY61-3606 in colorectal cancer cells.
Methods
Cell lines, knockdowns, and drug treatments
All colon cancer cell lines were maintained in DMEM
supplemented with penicillin (100 units/mL), streptomycin
(100 mg/mL), and 10% fetal bovine serum (FBS). The rectal
cancer cell line (Car1) was maintained in DMEM/F12 supple-
mented with penicillin (100 units/mL)/streptomycin (50 mg/mL),
and 5% FBS. Knockdowns were achieved with pSICOR or
pLKO lentiviral vectors [16]. The target sequences for knock-
downs can be found in Table S2. In drug treatment experiments,
cells were plated for 24 hours prior to exposure to drug. AZ-628
was obtained from AstraZeneca. CI-1040 was obtained from
Pfizer. R406 was synthesized in the Gray laboratory. BAY61-3606
and IKK VII were purchased from EMD Biosciences. BAY
derivatives were synthesized for this study.
Cell cycle analysis and cell viability assays
Cell cycle analysis was performed via FACS-based propidium
iodide quantification, using standard methods. To measure cell
viability, cells were grown in 96-well plates in the presence or
absence of drug for 72 hours, fixed with 4% paraformaldehyde,
and then stained with Syto60 (Invitrogen). Plates were imaged and
quantified using the LiCor Odyssey system (LiCor).
Bio-Plex signaling assays
The Bio-Plex assay system was used to measure signaling in
drug-treated cells. Briefly, cells were incubated in the presence of
drug for various amounts of time and then lysed in Bio-Rad cell
lysis buffer (Bio-Rad). Protein quantification was performed using
BCA assay (Pierce) and 5 mg of protein from each sample was used
for Bio-Plex analysis. Phospho-signaling assays were performed
using available phospho-signaling assay kits and quantified on
a Bio-Plex 200 system (Bio-Rad): p-Ikba (Ser32/Ser36), p-JNK
(Thr183/Tyr185), p-MEK1 (Ser217/Ser221), p-ERK1/2
(Thr202/Tyr204, Thr185/Tyr187), p-p90RSK (Thr359/
Ser363), p-p38 (Thr180/Tyr182), p-c-JUN (Ser63), p-ATF2
(Thr71), p-AKT (Ser473), p-S6 (Ser235/Ser236), p-STAT3
(Ser727), p-STAT3 (Tyr705), and p-GSK3a/b (Ser21/Ser9).
Bio-Plex assay for total MEK1 was also performed as a loading
control. All signals were normalized to a common control cell line
lysate in order for assays between plates to be comparable.
Biochemical activity assays
The biochemical activity of BAY61-3606 and derivatives were
measured in two ways. First, we used Ambit’s KINOMEscanTM
technology to identify those kinases that are inhibited for substrate
binding by the compounds, all assayed at 1 mM. Second, we used
Invitrogen’s SelectScreenH Biochemical Kinase Profiling Service
to determine the in vitro IC50s for the compounds against specific
kinases.
Chemical derivation of BAY61-3603
Details on the synthesis of BAY derivatives, and the structures of
those derivatives, can be found in Figure S5.
Results
AZ-628 and BAY61-3606 suppress growth in cells
expressing K-RASG13D
In an effort to identify novel therapeutic targets for colorectal
cancers expressing mutant K-RAS, we performed a screen for
small molecule kinase inhibitors that affect viability in a genotype-
specific manner. In these studies, we utilized a set of isogenic colon
cancer cell lines that differ only in their K-RAS mutation status.
The parental cell lines, HCT-116 and DLD-1, carry a heterozy-
gous activating mutation in K-RAS (G13D/+). The derivative cell
lines, HKe-3 and DKs-8, retain the wild-type allele, but have lost
the mutant allele of K-RAS by virtue of gene targeting [17].
Consistent with our previous work [9], we found that K-RAS
mutant cells were hypersensitive to AZ-628, a pan-RAF inhibitor
[18,19], compared to wild-type cells, but insensitive to CI-1040,
a MEK inhibitor [6] (Fig. 1a). We also found that BAY61-3606,
a Spleen Tyrosine Kinase (SYK) inhibitor, affected overall viability
in HCT-116 and DLD-1 cells compared to HKe-3 and DKs-8
cells (Fig. 1a, Fig. S1a).
To determine how BAY61-3606 affected viability of cells
expressing mutant K-RAS, we analyzed the cell cycle of cells
treated with the drug. We found that BAY61-3606 did not alter
the cell cycle profile of DLD-1 cells, nor did it induce apoptosis
(Fig. 1b). In contrast to colorectal cancer cells expressing mutant
K-RAS, cell lines that express mutant B-RAF were sensitive to
inhibition of MEK and treatment with CI-1040 induced G1 arrest
[6] (Fig. 1b, c). Interestingly, we found that B-RAF mutant cells
lines were also sensitive to BAY61-3606 and that CI-1040 and
BAY61-3606 cooperated to produce an enhanced negative effect
on viability of cells expressing activated B-RAF (Fig. 1c). Taken
together, these observations suggested (1) that BAY61-3606
inhibits a protein that is required for overall viability in cells
expressing mutant K-RAS or B-RAF and (2) that BAY61-3606
targets a pathway that is independent of canonical MAPK/ERK
signaling.
To test the second part of this hypothesis directly, we measured
the activation state of MEK and ERK in cells that were treated
with BAY61-3606. We found that inhibition of RAF with AZ-628
suppressed MEK and ERK phosphorylation, but that BAY61-
3606 was unable to do so (Fig. 1d). Thus, while AZ-628 and
BAY61-3606 both selectively affect viability in K-RAS mutant
cells, they appear to do so through distinct pathways, with BAY61-
3606 targeting a pathway that is independent of MEK and ERK.
Selective Activity of BAY61-3606
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SYK is not the target of BAY61-3606 in cells expressing
mutant K-RAS
Given that BAY61-3606 was originally developed as an ATP-
competitive inhibitor of SYK [14], it was not surprising that it
appeared to target a MEK/ERK-independent pathway. Never-
theless, HCT-116 cells, which are sensitive to BAY61-3606, do not
express detectable levels of SYK, suggesting that it may not be the
target of BAY61-3606 in this context. To explore this further, we
used lentiviral shRNA to knock down SYK in DLD-1 cells
(Fig. 2a). Knockdown of SYK did not affect overall growth rate
nor did it significantly affect the response of DLD-1 cells to
BAY61-3606 (Fig. 2b). Moreover, treatment of cells with R406,
a structurally distinct inhibitor of SYK, did not result in
a preferential effect in cells expressing mutant K-RAS (Fig. 2b).
Taken together, these results suggested that SYK was not the
relevant target of BAY61-3606 in colorectal cancer cells expressing
mutant K-RAS.
Figure 1. BAY61-3606 affects viability in cells expressing mutant K-RAS or B-RAF through a MAPK-independent pathway. (a) Cell
viability quantified by Syto60 after 72 hours of AZ-628, CI-1040 or BAY61-3606 treatment in HCT-116 (K-RASG13D/+, red) or HKe-3 (K-RAS2/+, blue) cell
lines. Relative cell viability was normalized to DMSO vehicle treated control for each cell line. Error bars represent SEM for 3 independent experiments.
Cells expressing mutant K-RAS were relatively sensitive to AZ-628 and BAY61-3606, but not CI-1040. (b) Cell cycle profiles, as determined by
propidium iodide staining, of colorectal cancer cells with mutant B-RAF (HT-29) treated with CI-1040 or mutant K-RAS (DLD-1) treated with BAY61-
3606. While inhibition of MEK induces G1 arrest in HT-29 cells, as evidenced by the loss of the 4N peak, BAY61-3606 did not appear to alter the profile
of DLD-1 cells. (c) Cell viability of colorectal cancer cells expressing mutant B-RAF (V600E) after 72 hours of treatment with BAY61-3606 and/or CI-
1040. Cells expressing mutant B-RAF (HT-29 – solid outline and RKO – dotted outline) were sensitive to both BAY61-3606 and CI-1040 and these two
inhibitors cooperated to produce an enhanced response. (d) Phospho-MEK1 (Ser217/Ser221) and phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187)
levels in K-RAS wild-type and mutant cells after 45 minute exposure to 1 mM AZ-628, 1 mM BAY61-3606, or vehicle control. Signals were measured
using Bio-Plex assays. Relative signal was normalized to a master control lysate. AZ-628 treatment reduced the level of phospho-MEK and phospho-
ERK, but BAY61-3606 did not.
doi:10.1371/journal.pone.0041343.g001
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BAY61-3606 targets a small number of kinases
We hypothesized that the activity of BAY61-3606 in colon
cancer cells was due to an ‘‘off-target’’ effect of the inhibitor, yet
little was known about the promiscuity of this particular
compound. To identify other potential targets of BAY61-3606,
we first assayed the ability of BAY61-3606 to competitively inhibit
active site binding in a panel of 402 kinases. We found that 1 mM
BAY61-3606 inhibited binding by greater than 90% for only 15
kinases (Fig. 3a, Table 1, Table S1), indicating that it is a highly
selective inhibitor, similar in selectivity to two clinical kinase
inhibitors, Imatinib and Gefitinib [20]. Since inhibition of active
site binding may, or may not, be directly correlated with inhibition
of kinase activity, we performed a secondary analysis in which we
determined the in vitro IC50 values for BAY61-3606 against many
of these candidate targets. This study revealed MAP4K2, a STE-
20 family kinase, as the kinase most sensitive to BAY61-3606, with
an in vitro IC50 of 11.3 nM (Table 1).
Genetic analysis of potential BAY61-3606 targets
To follow-up on our biochemical analysis of BAY61-3606
activity, we used lentiviral shRNA to determine whether
knockdown of any of the potential targets was able to phenocopy
treatment with the drug (i.e. to selectively affect viability of K-RAS
mutant cells) (Fig. S1c, Table S2). For these studies, we utilized the
DLD-1/DKs-8 isogenic cell lines because we had used this pair for
genetic analysis of SYK (Fig. 2). Knockdown of only one of the
potential targets that we assayed, HIPK2, was able to selectively
affect viability of K-RAS mutant cells (Fig. 3b). Nevertheless, we
could only identify a single shRNA sequence that produced
adequate knockdown of this target. As a result, this study was
suggestive, but not conclusive, of a role for HIPK2 as a target of
BAY61-3606 in cells expressing mutant K-RAS. We sought an
independent way to identify the target of BAY61-3606.
Identification of biologically active BAY61-3606
derivatives
Secondary to our genetic analysis, we took a chemical approach
to studying BAY61-3606. In this study, we generated 30
structurally related derivatives of BAY61-3606 and assayed their
ability to selectively affect viability of cells expressing mutant K-
RAS (Fig. S2). Of these 30 derivatives, only one (derivative 6)
retained its selectivity with potency similar to the parent
compound (Fig. 4a, b, Fig. S1b). Others (e.g. derivative 8) retained
selectivity but lost potency. To address the selectivity of BAY
derivative 6 more broadly, we assessed its activity in a panel of
colorectal cancer cell lines that were either mutant for wild-type
for K-RAS. Consistent with our analysis of isogenic pairs, 4/5 cell
lines expressing mutationally activated K-RAS responded to BAY
derivative 6, while 0/3 cell lines expressing wild-type K-RAS
responded (Fig. S3).
To compare with BAY61-3606, we assayed the ability of several
derivatives to competitively inhibit active site binding in a large
panel of kinases. Remarkably, each of the derivatives that were
tested essentially lost their ability to competitively inhibit active site
binding of the 402 kinases that were analyzed, including HIPK2
(Fig. S4). Consistent with this observation, in vitro activity assays
revealed a loss of kinase inhibition activity for the two derivatives
tested (Fig. S5).
BAY61-3606 targets MAP4K2 to affect the response of
wild-type cells to AZ-628
In analyzing the relative activities of AZ-628 and BAY61-3606,
we tested whether these two compounds would cooperate to
produce an enhanced effect in cells expressing mutant K-RAS,
similar to the cooperative effect seen with CI-1040 and BAY61-
3606 in cells expressing mutant B-RAF. AZ-628 and BAY61-3606
did not cooperate in HCT-116 cells (Fig. 5a), however, suggesting
that they may target a common pathway. Interestingly these two
inhibitors did cooperate to negatively affect viability of cells
expressing wild-type K-RAS. In essence, HKe-3 cells that were
formally resistant to AZ-628 became sensitive when they were also
treated with BAY61-3606 (Fig. 5a). BAY derivative 6, which
retained its ability to selectively suppress proliferation in cells
expressing mutant K-RAS (Fig. 4b), lost its ability to cooperate
with AZ-628 in cells expressing wild-type K-RAS (Fig. 5b).
With the exception of SYK, BAY61-3606 was more than 10-
fold more effective at inhibiting MAP4K2 than any other kinase.
Moreover, BAY derivative 6 lost its ability to effectively inhibit the
in vitro kinase activity of MAP4K2 (Fig. S5). Based on these
observations, we explored whether MAP4K2 plays a role in the
sensitivity of wild-type and K-RAS mutant cells to BAY61-3606.
HKe-3 and Dks-8 cells lacking MAP4K2 were hypersensitive to
AZ-628, while MAP4K2 knockout had no effect on the response
of HCT-116 or DLD-1 cells (Fig. 5c, Fig. S6a). We reasoned that
if inhibition of MAP4K2 by BAY61-3606 accounted for the
altered response of wild-type cells to AZ-628, then K-RAS wild-
type cells lacking MAP4K2 would not be further sensitized to AZ-
628 by treatment with BAY61-3606. As predicted, BAY61-3606
and AZ-628 failed to cooperatively affect viability in HKe-3 cells
lacking MAP4K2 (Fig. 5d). The results strongly suggest that
Figure 2. Inhibition of SYK is not responsible for the BAY61-
3606 effect on cell viability in colorectal cancer cells. (a)
Knockdown of SYK protein in DLD-1 cells via shRNA, as shown by
Western Blotting. The Ramos (R) cell line, a hematopoetic cell line with
a high expression of SYK, was used as a positive control. (b) Cell viability
of DLD-1 cells (red), and its K-RAS wild-type (DKs-8 – blue) and SYK
knockdown (red shaded) derivatives after 72 hours of treatment with
1 mM of BAY61-3606 or R406, a distinct SYK inhibitor. Relative cell
viability was normalized to DMSO vehicle treated control for each cell
line. Error bars represent SEM for 3 independent experiments. DLD-1
cells and its K-RAS wild-type derivative did not exhibit sensitivity to
R406, while knocking down SYK in DLD-1 cells only minimally affected
its sensitivity to BAY61-3606.
doi:10.1371/journal.pone.0041343.g002
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BAY61-3606 alters the response of cell expressing wild-type K-
RAS to AZ-628 by inhibiting the kinase activity of MAP4K2.
MAP4K2 activates the NFkB pathway to counteract
AZ628-dependent growth inhibition
Given that MAP4K2 is important for the response of wild-type
cells to AZ-628, we next asked how MAP4K2 functions to regulate
the response to RAF inhibition. To identify the pathway
responsible for MAP4K2 action, we used Bio-Plex phospho-
protein analysis to measure the effects of MAP4K2 knockdown on
various cellular signaling pathways. In total, we profiled 13
phospho-proteins: Ikba (Ser32/Ser36), JNK (Thr183/Tyr185),
MEK1 (Ser217/Ser221), ERK1/2 (Thr202/Tyr204, Thr185/
Tyr187), RSK (Thr359/Ser363), p38 (Thr180/Tyr182), c-JUN
(Ser63), ATF2 (Thr71), AKT (Ser473), S6 (Ser235/Ser236),
STAT3 (Ser727), STAT3 (Tyr705), and GSK3a/b (Ser21/Ser9)
(Fig. S7). We found two differences between HKe-3 and HCT-
116 that we posited might be related to the function of MAP4K2.
First, we found that the basal level of Ikba phosphorylation was
significantly lower in HCT-116 than in HKe-3 cells, suggesting
that NFkb signaling is suppressed in cells expressing activated K-
RAS (Fig. S7). Ikba phosphorylation was further induced in HKe-
3 cells after treatment with AZ-628 and this induction was
dependent upon MAP4K2 (Fig. 6a). This observation is consistent
with previous studies linking MAP4K2 to NFkb signaling [21].
Second, we found that JNK was strongly activated in HKe-3 cells
after treatment with AZ-628 (Fig. S7). Although MAP4K2 has
been previously linked to JNK signaling, this activation did not
appear to require MAP4K2 (Fig. S6b).
Since NFkb was appeared to hyper-activated in wild-type cells
in a MAP4K2-dependent manner, we surmised that inhibition of
the NFkb pathway would have the same effect as BAY61-3606 or
MAP4K2 knockdown. That is, we expected that inhibition of
NFkb would increase the sensitivity of K-RAS wild-type cells to
AZ-628 without affecting the sensitivity of K-RAS mutant cells. As
predicted, inhibition of NFkb increased the sensitivity of HKe-3
and Dks-8 cells to AZ-628, essentially phenocopying MAP4K2
knockdown (Fig. 6b, Fig. S6c). By contrast, inhibition of JNK did
not alter the sensitivity of HKe-3 cells to AZ-628 (Fig. S6d).
Further, as with BAY61-3606 treatment, knockdown of MAP4K2
abolished the ability of NFkb inhibition to sensitize wild-type cells
to AZ-628 (Fig. 6c). From these data, we conclude that MAP4K2
functions upstream in the NFkb pathway to regulate the response
of colorectal cancer cells to inhibition of RAF.
Discussion
K-RAS is mutationally activated in approximately 40% of
colorectal cancers [2]. Activated K-RAS is thought to confer
oncogenicity via its canonical downstream signaling pathways, for
example the RAF-MEK-ERK (MAPK) signaling cascade. Con-
sistent with this idea, activating mutations in B-RAF occur in 15%
of colorectal cancers and they are mutually exclusive with K-RAS
mutations [22]. Nevertheless, inhibition of MAPK signaling,
typically by directly inhibiting MEK, has been largely ineffective
in treating K-RAS mutant colorectal cancer [9,23]. The lack of
efficacy of MEK inhibitors in this context may be due to the
pleiotropic function of K-RAS, which has been shown to promote
Figure 3. Identification and attempted validation of BAY61-3606 targets. (a) TREEspot image representing the inhibitory activity of BAY61-
3606. Kinases that are inhibited for ATP binding by BAY61-3606 are indicated by red dots on the phylogenetic tree of kinases. The size of the red dot
corresponds to the amount of inhibition by 1 mM BAY61-3606. The identity of the individual kinases can be found in Table S1. (b) Cell viability
quantified by Syto60 after shRNA-mediated knockdown of the potential BAY61-3606 targets in DLD-1 (red) or DKs-8 (blue) cell lines. Relative cell
viability is normalized to the parental cell lines infected with vector only. Error bars represent SEM for 2 independent experiments.
doi:10.1371/journal.pone.0041343.g003
Table 1. Activity of BAY61-3606 against selected kinases.
Kinase
% inhibition
ATP binding* IC50 (nM)**
CDK9 44 34.8
GSK3a 83 89.2
GSK3b 61 123
HIPK1 91.2 4240
HIPK2 91 248
MAP4K2 94 11.3
NEK1 73 159
ROCK1 96.8 144
ROCK2 87 166
SYK 93.9 25.5
*% inhibition of ATP binding as assessed by KINOMEscanTM (Ambit Biosciences).
**In vitro IC50 were determined by SelectScreenH (Invitrogen).
doi:10.1371/journal.pone.0041343.t001
Selective Activity of BAY61-3606
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Figure 4. Biological activities of BAY61-3606 derivatives. (a) GI50 values for BAY61-3606 derivatives performed in HCT-116 (red) or HKe-3
(blue) cells. Derivative 6 was chosen for further study for its increased potency and specificity for K-RAS mutant cells. (b) Cell viability quantified by
Syto60 after 72 hours exposure to BAY derivative 6 in HCT-116 (red) or HKe-3 (blue) cells. Relative cell viability was normalized to DMSO vehicle
treated control for each cell line. Error bars represent SEM for 3 independent experiments. HCT-116 cells were relatively sensitive to BAY derivative 6.
doi:10.1371/journal.pone.0041343.g004
Figure 5. MAP4K2 is a target for BAY61-3606 that modulates the response of wild-type cells to AZ-628. (a) Cell viability quantified by
Syto60 after 72 hours of combinatorial treatment with varying concentrations of BAY61-3606 and 1 mM AZ-628 in HCT-116 (red line) or HKe-3 (blue
lines) cells. Relative cell viability was normalized to DMSO vehicle treated control for each cell line. Error bars represent SEM for 3 independent
experiments. The two inhibitors cooperate in wild-type cells, but not in cells expressing mutant K-RAS. (b) Cell viability after 72 hours of
combinatorial treatment with varying concentrations of BAY derivative 6 and 1 mM AZ-628 in HCT-116 and HKe-3 cells. BAY derivative 6 does not
confer additional sensitivity to AZ-628 upon HKe-3 cells. (c) Cell viability quantified by Syto60 after 72 hours of AZ-628 treatment in HCT-116 or HKe-3
cell lines with MAP4K2 knockdown. Loss of MAP4K2 does not affect AZ-628 response in cells expressing mutant K-RAS, but enhances the effect of AZ-
628 in cells expressing wild-type K-RAS. (d) Cell viability after 72 hours of combinatorial treatment with 1 mM BAY61-3606 and 1 mM AZ-628 (shaded)
or 1 mM AZ-628 alone (clear) in HKe-3 cells with MAP4K2 knockdown. Relative cell viability was normalized to 1 mM AZ-628 treated samples. In
parental HKe-3 cells, BAY61-3606 confers sensitivity to AZ-628. Upon loss of MAP4K2, BAY61-3606 no longer sensitizes.
doi:10.1371/journal.pone.0041343.g005
Selective Activity of BAY61-3606
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transformation through the PI3K and RAL effector pathways in
addition to MAPK [24,25]. Yet, PI3K pathway mutations also
occur in colorectal cancers and are often coincident with K-RAS
mutations, suggesting that PI3K is not a common effector of K-
RAS signaling in colon cancer [26]. And while PI3K mutations
have been associated with resistance to MEK inhibitors in cancer
cell lines [27,28], K-RAS mutant colon cancers from genetically
engineered mice are intrinsically resistant to inhibition of MEK
[9]. Our data are consistent with an alternative explanation for the
lack of efficacy of MEK inhibitors in colorectal cancers expressing
mutant K-RAS – that there exists an alternate/parallel pathway
downstream of B-RAF that mediates K-RAS-induced oncogenic-
ity.
In our study, we characterized the activity of a small molecule,
BAY61-3606, that preferentially affected viability in colorectal
cancer cells expressing mutant K-RAS compared to isogenic cells
expressing only wild-type K-RAS (Fig. 1a, Fig. S1a). Since
BAY61-3606 is an ATP-competitive kinase inhibitor, its ability
to preferentially affect cells expressing mutant K-RAS initially
suggested that it targets a kinase functioning downstream of K-
RAS to promote proliferation. We have previously shown that K-
RAS promotes colon cancer cell proliferation through a RAF-
dependent, but MEK-independent, signaling pathway [9]. Three
pieces of evidence implicate BAY61-3606 as an inhibitor of this
MEK-independent pathway downstream of RAF. First, BAY61-
3606 did not cooperate with AZ-628 in cells expressing mutant K-
RAS (Fig. 5a), suggesting that these inhibitors targeted a common
pathway. Second, BAY61-3606 affected growth in KRAS mutant
cells, but, unlike AZ-628, did not affect the phosphorylation state
of MEK or ERK (Fig. 1d). Finally, BAY61-3606 slowed the
growth of colorectal cancer cells expressing mutant B-RAF and
cooperated with a MEK inhibitor to produce an enhanced
response in these cells (Fig. 1c).
Although BAY61-3606 was initially characterized as an ATP
competitive kinase inhibitor, its selectivity for decreasing the
viability of K-RAS mutant cells may not require this activity. Our
studies of BAY61-3606 derivatives demonstrate that those lacking
the ability to affect active site binding can still maintain their
ability to selectively affect cell viability. One possible explanation
for this observation is that the relevant target of BAY61-3606 and
its biologically active derivatives is a non-kinase protein. Aside
from inhibiting kinases, ATP analogs can affect biology through
other processes, including nucleic acids synthesis [29,30] and
microtubule motor transport [31]. Alternately, the relevant target
may not be among the 402 kinases that were surveyed in our assay
or BAY61-3606 and derivatives could inhibit kinase activity
without affecting active site binding. If so, they would not score in
our screen.
In addition to its activity in cells expressing mutant K-RAS or
B-RAF, we also identified a secondary biological effect of BAY61-
3606; it conferred upon wild-type cells, which are normally
resistant to AZ-628, sensitivity to RAF inhibition (Fig. 5a). Using
a variety of approaches, we identified MAP4K2 as the target for
BAY61-3606 in wild-type cells. MAP4K2 (also known as GCK,
for Germinal Center Kinase) is a member of the STE20 family of
protein kinases [32]. MAP4K2 has been shown to play a role in
the inflammatory process and is activated by inflammatory stimuli
such as TNFa, IL-1, and LPS [33,34]. MAP4K2 interacts with
TNFR-associated factor 2 (TRAF2) and MAPK/ERK kinase
kinase 1 (MEKK1), thereby linking TNF signaling to activation of
the pro-death JNK and p38 MAPK pathways [35]. Aside from
activating pro-death signaling pathways, the TNF receptor
pathway can also promote cell survival through the NFkb
pathway. Incidentally, the NFkb pathway is recruited by the
TRAF2 complex upon TNFR activation [36]. Moreover,
MAP4K2 has been shown to positively regulate NFkb to protect
melanoma cells from UV-induced apoptosis [21].
Inhibition of RAF by AZ-628 leads to MAP4K2-dependent
activation of NFkb signaling in wild-type cells, presumably to
ensure cell survival (Fig. 6a). To maintain reliable behavior, cell
signaling networks have evolved robust feedback mechanisms in
order to minimize the effects of focal perturbations, which can
arise from various stresses that cells encounter. The robustness of
a signaling network is evident in its compensatory behavior given
the activation or inactivation of a single pathway. For example, it
has been demonstrated that RAF pathway activity is anti-
correlated to PI3K signaling through global network feedback
[37]. Consequently, pharmacologic inhibition of MEK results in
PI3K pathway activation, resulting in cell survival [38]. Similarly,
inhibition of mTOR, a downstream effector of PI3K, has been
Figure 6. MAP4K2 modulates NFkb signaling. (a) Time course of phospho-Ikba (Ser32/Ser36) activation after 1 mM AZ-628 treatment in HCT-
116 (red lines) or HKe-3 (blue line) cells with MAP4K2 knock down, as measured via Bio-Plex. Relative signal was normalized to a master control lysate.
Error bars represent SEM for 3 independent experiments. NFkb signaling was enhanced in HKe-3 cells after exposure to AZ-628 and this was
dependent upon MAP4K2. (b) Cell viability quantified by Syto60 after 72 hours of combinatorial treatment with IKK inhibitor VII and 1 mM AZ-628.
Relative cell viability was normalized to DMSO vehicle treated control for each cell line. Like BAY61-3606, IKK inhibitor VII enhanced the effect of AZ-
628 specifically in K-RAS wild-type cells. (c) Cell viability after 72 hours of combinatorial treatment of 1 mM IKK inhibitor VII and 1 mM AZ-628 (shaded)
or 1 mM AZ-628 alone (clear) in HKe3 cells with MAP4K2 knockdown. Relative cell viability was normalized to 1 mM AZ-628 treated samples. Loss of
MAP4K2 abrogated the ability of IKK inhibitor VII to sensitize HKe-3 cells to AZ-628.
doi:10.1371/journal.pone.0041343.g006
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shown to increase ERK activity [39]. Given the large number of
mutations that cancer cells accumulate, oncogenic signaling
networks have evolved to be very different from signaling networks
in normal cells. Whereas cancer cells have evolved such that they
are robust to growth and proliferation, there may be areas in their
networks that are more fragile to perturbations than their wild-
type counterparts, which can be exploited for therapeutic
purposes.
While our studies specifically address the function of the small
molecule kinase inhibitor BAY61-3606 in colorectal cancer cells,
they more generally address the varied activities that kinase
inhibitors can have in cancer cells. Although inhibitor promiscuity
is often viewed in a negative light, the ability of a given small
molecule to target multiple kinases may, in fact, be beneficial for
targeting diverse genotypic classes of cancer.
Supporting Information
Figure S1 Genetic analysis of BAY61-3606 response in
DLD-1 cells. (a) Cell viability quantified by Syto60 after
72 hours of BAY61-3606 treatment in DLD-1 (K-RASG13D/+,
red) or DKs-8 (K-RAS2/+, blue) cell lines. Relative cell viability
was normalized to DMSO vehicle treated control for each cell
line. Error bars represent SEM for 3 independent experiments.
The differential response in the two cell lines is statistically
significant (p = 0.019 at 1 mM). (b) Cell viability quantified by
Syto60 after 72 hours of BAY derivative 6 treatment in DLD-1
(K-RASG13D/+, red) or DKs-8 (K-RAS2/+, blue) cell lines.
Relative cell viability was normalized to DMSO vehicle treated
control for each cell line. Error bars represent SEM for 3
independent experiments. (c) Validation of shRNAs. Relative gene
expression of shRNA-mediated knockdowns of potential BAY61-
3606 targets in DLD-1 (red) and DKs-8 (blue) cells. Gene
expression is measured via Taqman assay and calculated using
standard methods in reference to the housekeeping gene TBP.
Error bars represent SEM for 3 independent experiments.
(PDF)
Figure S2 Chemical derivation of BAY61-3606 deriva-
tives. (a) Synthesis of BAY derivative 6. To a stirred solution of
5,7-dichloroimidazo [1,5-f] pyrimidine (186.0 mg, 1.0 mmol) in
DMF (5.0 mL) was added 2-methoxybenzenamine (123.0 mg, 1.0
equiv). After 1 h heating at 70u, the mixture was purified on silica
gel column with methylene chloride and methanol (10:1) as eluent
to give of 7-chloro-N-(2-methoxyphenyl)imidazo [1,5-f] pyrimidin-
5-amine(245 mg, yield 89%). To a solution of 7-chloro-N-(2-
methoxyphenyl)imidazo [1,5-f] pyrimidin-5-amine (200.0 mg,
0.73 mmol) and 3,4-dimethoxyphenylboronic acid (160.0 mg,
1.2 equiv) in 5.0 mL 1,4-dioxane was added Bis(triphenylpho-
sphine) palladium(II) dichloride (51.0 mg, 0.1 equiv) as catalyst
and saturated potassium carbonate aqueous solution (2.0 mL) as
base. The mixture was heated for 2 h at 80u and then was diluted
with chloroform and 2-propanol (50 mL, 4:1). The organic layer
was washed with water, brine and was dried with sodium sulfate.
After removal of solvent, the crude was purified by column with
methylene chloride and methanol (10:1) to give BAY derivative 6
(192.0 mg, 70%). 1H NMR (DMSO-d6) 9.05 (s, 1 H), 8.22 (s, 1 H),
7.23 (d, J=7.8 Hz, 1 H), 7,61-7.53 (m, 4 H), 7.26 (t, J=7.8 Hz, 1
H), 7.16 (d, J=8.4 Hz, 1 H), 7.04 (t, J=7.8 Hz, 1 H), 6.94 (d,
J=8.4 Hz, 1 H), 3.80 (s, 3 H), 3.75 (s, 3 H), 3.72 (s, 3 H). (b)
Chemical structures of all BAY derivatives.
(PDF)
Figure S3 Evaluation of BAY derivative 6 activity in
colorectal cancer cell lines. Cell viability quantified by Syto60
after 72 hours of BAY derivative 6 treatment in 5 cell lines
expressing mutant K-RAS and in 3 cell lines expressing wild-type
K-RAS. Relative cell viability was normalized to an untreated
control for each cell line. Error bars represent SEM for 3
independent experiments. With the exception of GP5d (highlight
in bold red), all of the cell lines expressing mutant K-RAS respond
to BAY derivative 6.
(PDF)
Figure S4 BAY61-3606 derivatives lose ATP competitive
activity. TREEspot images for five different derivatives of
BAY61-3606. Both inhibitors that retained selectivity for K-RAS
mutant cells (e.g. 6 and 8) and those that lost selectivity (e.g. 1, 21,
and 28), failed to effectively inhibit ATP binding by the majority of
kinases that were assayed.
(PDF)
Figure S5 Kinase inhibition profiles of BAY61-3606 and
its derivatives. Inhibitor activity was measured using Invitro-
gen’s SelectScreenH Biochemical Kinase Profiling Service.
(PDF)
Figure S6 Evaluation of MAP4K2 in the BAY61-3606
response. (a) Cell viability quantified by Syto60 after 72 hours of
AZ-628 treatment in DLD-1 or DKs-8 cell lines with MAP4K2
knockdown. Loss of MAP4K2 does not affect AZ-628 response in
cells expressing mutant K-RAS, but enhances the effect of AZ-628
in cells expressing wild-type K-RAS. (b) Time course of phospho-
JNK (Thr183/Tyr185) after 1 mMAZ-628 treatment in HCT-116
(red lines) or HKe-3 (blue line) cells with MAP4K2 knock down, as
measured by Bio-Plex. Relative signal was normalized to a master
control lysate. Error bars represent SEM for 3 independent
experiments. JNK signaling was enhanced in HKe-3 cells but was
independent of MAP4K2. (c) Cell viability quantified by Syto60
after 72 hours of combinatorial treatment with IKK inhibitor VII
and 1 mM AZ-628. Relative cell viability was normalized to
DMSO vehicle treated control for each cell line. Like BAY61-
3606, IKK inhibitor VII enhanced the effect of AZ-628
specifically in K-RAS wild-type cells. (d) Cell viability quantified
by Syto60 after 72 hours of combinatorial treatment with the JNK
inhibitor SP600125 and 1 mM AZ-628. Relative cell viability was
normalized to DMSO vehicle treated control for each cell line.
Unlike BAY61-3606, SP600125 did not affect AZ-628 sensitivity
in K-RAS wild-type cells.
(PDF)
Figure S7 Signaling pathway activity in response to AZ-
628. Phospho-protein measurements were made after 45 minutes
of exposure to 1 mM AZ-628 or DMSO vehicle control treatment
in HCT-116 (red squares) or HKe-3 (blue dots) cells. X’s represent
measurements from cells with MAP4K2 knock down. All
measurements were quantified by Bio-Plex signaling assays.
Relative signal was normalized to a master control lysate.
(PDF)
Table S1 Active site binding inhibition data.
(PDF)
Table S2 shRNAs used in this study.
(PDF)
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